Form 4: Ultragenyx CEO Emil Kakkis Sells 20,000 Shares
SEC Form 4 Filing
Ultragenyx Pharmaceutical Inc.'s CEO, Emil D. Kakkis, sold 20,000 shares of common stock at an average price of $50.17 on August 6, 2024.
Summary
- On August 6, 2024, Emil D. Kakkis, the President and CEO of Ultragenyx Pharmaceutical Inc., sold 20,000 shares of common stock.
- The shares were sold at a weighted average price of $50.17, with individual transactions ranging from $50.00 to $50.87.
- Following the transaction, Kakkis directly owns 564,597 shares and indirectly owns 2,243,985 shares through a living trust.
- The direct holdings include shares underlying Restricted Stock Units (RSUs) and shares acquired through the company's Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, reporting a stock sale by the CEO. It's a neutral event in itself, with no inherent positive or negative sentiment. The impact on investors depends on their interpretation of the sale.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's valuation and future prospects. However, these sales can be for various personal financial planning reasons and do not always indicate a negative outlook.
Stakeholder Impact
- Shareholders may react to the CEO's stock sale, potentially influencing the stock price.
- The sale could be perceived as a lack of confidence in the company's future performance, although it could also be for personal financial reasons.
Key Dates
| Date | Description |
|---|---|
| June 18, 2009 | Date of Emil Kakkis and Jenny Soriano Living Trust |
| April 30, 2024 | Date of acquisition of 684 shares under the Company's A&R 2014 Employee Stock Purchase Plan |
| August 6, 2024 | Date of the stock sale transaction |
| August 7, 2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.